<![CDATA[Sequencing Therapy After ESA Failure in RS-Negative Lower-Risk MDS]]>

<![CDATA[Rationale and Timing: The Evolving Role of BCMA-Targeted Therapies in Relapsed/Refractory Multiple Myeloma ]]>

<![CDATA[BCMA Biology, Mechanisms of Action, and Unmet Needs in Relapsed/Refractory Multiple Myeloma]]>

Therapeutic inhibition of telomeric DNA damage response rescues hematopoietic dysfunction driven by telomere shortening and aging

Therapeutic inhibition of telomeric DNA damage response rescues hematopoietic dysfunction driven by telomere shortening and aging

Methylation-based ctDNA monitoring in metastatic breast cancer during CDK4/6 inhibitor therapy

Methylation-based ctDNA monitoring in 57 patients closely reflects outcomes in ER+, HER2- metastatic breast cancer during CDK4/6 inhibitor t

<![CDATA[From Observation to Treatment: The Role of Caregivers and Overcoming VMAT2 Inhibitor Complexities]]>

<![CDATA[Isatuximab Wins FDA Approval, Becoming Second Subcutaneous Anti-CD38 for Multiple Myeloma]]>